In a small Spanish phase II trial, the feasibility of adding trastuzumab, an anti-HER2 monoclonal antibody, to perioperative chemotherapy with capecitabine and oxaliplatin was determined in 36 patients with resectable HER2 positive gastric or GOJ adenocarcinoma, where the 18-month DFS was 71% [54]. Here, ERBB2 is linked to adenocarcinoma.